Transforming the Trajectory of Type 1 Diabetes

Prevention of any disease is challenging, and this is certainly true for T1D. Preventing T1D requires retraining the immune system. Specifically, it needs to deter the autoimmune attack on the body that destroys the insulin-producing beta cells in the pancreas, which results in T1D. Identifying prevention therapies is a long-term endeavor fraught with challenges, yet ultimately with great reward – and a priority for Helmsley. We anticipate that the research efforts we support will uncover new biomarkers of disease susceptibility along the way, in addition to other discoveries.


Finding Those At Risk

Preventing a disease requires first understanding the mechanisms that cause it, as well as knowing who is at risk for developing it. There are currently two common ways to determine if an individual is at risk of developing T1D. One is to screen for genetic predisposition. The second is to test for autoantibodies. Other metabolic measures can also help to stratify risk.

If someone is shown to have genetic risk, they can at a minimum be monitored to determine if they are crossing the threshold to autoimmunity. For those where autoimmunity is present, they can be monitored for changes in blood sugars that signal onset of clinical disease, with a goal of minimizing diabetic ketoacidosis, a potentially life-threatening complication too often present at diagnosis. There is a fundamental public health benefit to helping more people understand their potential risk for T1D and minimizing poor outcomes.


Stalling or Preventing Autoimmunity  

Monitoring is an important option, but far from sufficient for such a life-changing condition. Over the past decade Helmsley has partnered with organizations around the world to carry out clinical prevention trials. These include novel efforts to delay autoimmunity and are led by investigators who have expertise in T1D pathogenesis, immunology, and pancreatic biology, and who are also committed to understanding what triggers T1D in the first place.

Our largest investment has been in Europe to support the Global Platform for the Prevention of Autoimmune Diabetes (GPPAD); it has sites in Germany, the United Kingdom, Belgium, Sweden, and Poland. The network identifies newborns with a high genetic risk for developing T1D and offers participation in clinical trials to prevent it.


Revolutionizing Therapeutics

Helmsley also invests in discovering and developing new drugs that can halt or delay progression of T1D, before insulin is needed. Our partners span from academic research labs to biotech companies.

An important part of discovering new drugs is understanding the development of T1D in humans, not just in laboratory models. Understanding the human disease can reveal promising drug targets that are the most likely to be successful in clinical trials. For example, we fund studies examining unique clinical cases of T1D, such as families with a high prevalence of the disease, or long-term non-progressors—individuals with autoimmunity but who take years longer than most to progress to diabetes. These special cases may shine a spotlight on a key aspect of T1D development, and lead to new generalizable therapeutic strategies.

We also fund the development of new therapies, pushing them from the laboratory to clinical trials.  A promising class of drugs is targeted immunotherapies, which are designed specifically to tamp down autoimmunity and prevent further damage to pancreatic tissue while leaving other tissues untouched. These targeted immunotherapies are designed to be safer and more powerful than many existing drugs, which suppress both autoimmune and healthy immune reactions.


People with T1D know the impact of this disease on daily life all too well. What we don’t know, however, is how to eliminate the burden that accompanies it. The INNODIA consortium is driven to expand our knowledge of T1D progression and transform its trajectory.
What if we sought new discoveries by investigating the exceptions to the rule, the clinical outliers that are often ignored?

News & Insights

Published Wed Jan 6, 2021

T1D Program Director Gina Agiostratidou, PhD Interviewed by Grantee INNODIA

Helmsley T1D Program Director Gina Agiostratidou, PhD was recently interviewed by INNODIA, a Helmsley ...

Research Shows T1D Can Be Present Before 6 Months of Age

Helmsley-supported research in the journal Diabetologia has found that type 1 diabetes can be present before a baby reaches six months of age, and possibly even in the womb.

Research Shows T1D Can Be Present Before 6 Months of Age

“Saving Diabetes Research from the COVID-19 Crush”

"We have made sure that we consider new research projects carefully in the context of priorities and the pandemic." Learn from Helmsley Program Officer Anne Koralova Ph.D. in this article in Healthline about diabetes research in the time of COVID-19.
“Saving Diabetes Research from the COVID-19 Crush”

Parker Institute for Cancer Immunotherapy, JDRF, and the Helmsley Charitable Trust Form Cancer and Diabetes Research Initiative

Collaborative funds $10 million in research to understand, predict and prevent insulin-dependent diabetes following checkpoint therapy for cancer.

SAN FRANCISCO and NEW YORK – May 29, 2019 – Immunotherapy has become a...

Parker Institute for Cancer Immunotherapy, JDRF, and the Helmsley Charitable Trust Form Cancer and Diabetes Research Initiative